Evidence map›Paper›PMID 42365891›Full record

ReviewCancer letters2026

Multi-dimensional orchestration of binders for improved CAR-T immunotherapy.

Chaoyang Zhu, Zhiwu Jiang, Rui Jing, Wei Guo, Yong Lu

Abstract readReview
In one paragraph

Review in Cancer letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chaoyang ZhuHouston Methodist Neal Cancer Center, Weill Cornell Medicine, Houston, TX, 77030, USA. Electronic address: czhu@houstonmethodist.org.
Zhiwu JiangHouston Methodist Neal Cancer Center, Weill Cornell Medicine, Houston, TX, 77030, USA.
Rui JingHouston Methodist Neal Cancer Center, Weill Cornell Medicine, Houston, TX, 77030, USA.
Wei GuoHouston Methodist Neal Cancer Center, Weill Cornell Medicine, Houston, TX, 77030, USA.
Yong LuHouston Methodist Neal Cancer Center, Weill Cornell Medicine, Houston, TX, 77030, USA. Electronic address: ylu2@houstonmethodist.org.

Funding

Induction of autosis to overcome resistance in adoptive cell therapy for solid tumorsR01CA278911 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Yong Lu · 2023 to 2026
$2.3M
The Unique Roles of Tumor-Specific Th9 Cells for Solid Tumor EradicationR01CA258477 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI LU, YONG · 2021 to 2025
$1.9M
Eradication of Escaped Variant Tumor Cells for Cancer ImmunotherapyR01CA248111 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI LU, YONG · 2021 to 2025
$1.9M
P38 MAPK is a molecular switch that controls the acquired resistance in adoptive cell therapyR37CA251318 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI LU, YONG · 2020 to 2024
$1.8M
Decoupling acute toxicities and antitumor efficacy in adoptive cell therapyR01CA288403 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Yong Lu · 2024 to 2026
$1.8M
NCI NIH HHS R01 CA248111NCI NIH HHS R01 CA258477NCI NIH HHS R01 CA278911NCI NIH HHS R01 CA288403NCI NIH HHS R37 CA251318
6 · The paper itself

Abstract

The design of antigen-binding domains (binders) is emerging as a decisive frontier in chimeric antigen receptor (CAR)-T cell engineering. Rather than serving as passive recognition elements, binders actively shape antigen selectivity, signaling thresholds, exhaustion propensity, persistence, and toxicity. We propose that optimal CAR performance requires a multidimensional design strategy. Success cannot be achieved by maximizing a single variable like affinity. Designers must instead integrate epitope position, binding kinetics, avidity, molecular geometry, and biophysical stability. In this review, we synthesize recent advances showing how these parameters collectively govern immunological synapse formation, antigen-density discrimination, and functional durability. Importantly, we highlight that the consequences of binder design are increasingly evident not only in mechanistic and preclinical studies, but also in real-world clinical translation and commercial trajectories. We further examine how the binder landscape has expanded beyond conventional scFvs to include VHHs, monobodies, DARPins, D-domains, peptides, natural ligands, TCR-mimic binders, and de novo AI-designed proteins. Together, these advances support a shift from empirical binder selection to rational binder orchestration as a foundational principle for next-generation CAR-T immunotherapy.

Indexed as

Immunotherapy, AdoptiveNeoplasmsReceptors, Antigen, T-CellReceptors, Chimeric AntigenT-LymphocytesAnimalsAntigens, NeoplasmHumansAntigens, NeoplasmReceptors, Antigen, T-CellReceptors, Chimeric AntigenBindersCAR engineeringCAR-T immunotherapyClinical translationTumor-associated antigens

Identifiers

PMID42365891
PMCPMC13592024

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.